Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

To investigate effects of 3 years of GH treatment on glucose homeostasis and prevalence of metabolic syndrome (MS) in adults with PWS.

Why It Was Studied

Adults with PWS are predisposed to develop impaired glucose tolerance (IGT) and diabetes mellitus type 2 (DMT2).

Continuation of GH maintains body composition, but GH is known to induce insulin resistance, which might affect glucose homeostasis.

Who Took Part

According to the abstract, 43 adults were involved.

The age groups tagged for this paper are children and young adults.

43 young adults with PWS.

How the Study Was Run

In design terms this was an open-label study.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

What Was Measured

PubMed files the paper under topics including Body Composition, Glucose, Growth Hormone, Homeostasis, Human Growth Hormone, Metabolic Syndrome and Prader-Willi Syndrome.

The authors tagged it with the keywords OGTT, Prader Willi syndrome, adults and glucose homeostasis.

What This Means in Plain Language

The paper is an open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 43 adults.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.